Patient Care

Advances in Targeted Therapy for Breast Cancer

Author and Disclosure Information

 

References

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Click here to read the digital edition.

Pages

Recommended Reading

Dose-dense breast chemotherapy is also cost dense
Federal Practitioner
Delayed Adjuvant Chemotherapy Significantly Affects Breast Cancer Recovery
Federal Practitioner
USPSTF Supports Mammography Starting at Age 50
Federal Practitioner
False Estradiol Results From Interaction With Fulvestrant
Federal Practitioner
Phone monitoring program helps cut chemotherapy symptom severity
Federal Practitioner
Unraveling the Causes of Breast Cancer Disparities
Federal Practitioner
Are Breast Cancer Patients Satisfied With Their Care?
Federal Practitioner
‘Strong evidence’ links obesity to cancers
Federal Practitioner